HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Another breakthrough has been with ADCs in combination with other treatments, such as an immunotherapy that inhibits the ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

It represents 82% of the ADC pipeline in major APAC markets. A surge in antibody-drug conjugates (ADCs) is driving China to ...

First Drug Is Expected To Be Available In Market By 2029 Says Kuick In Its ReportDelhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated ...

Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...